Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / pleiotrophin



This biomarker is also known as:
  • heparin affin regulatory protein,
  • PTN,
  • heparin binding growth factor 8,
  • NEGF1,
  • HBGF8,
  • HBNF-1,
  • neurite growth-promoting factor 1,
  • pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1),
  • HBNF1,
  • heparin-binding brain mitogen,
  • heparin-binding growth-associated molecule,
  • HARP,
  • osteoblast-specific factor 1,
  • heparin-binding growth factor 8,
  • Heparin-binding growth-associated molecule,
  • OSF-1,
  • HBNF,
  • Heparin-binding neurite outgrowth-promoting factor 1,
  • Osteoblast-specific factor 1,
  • Heparin-binding growth factor 8,
  • Heparin-binding brain mitogen,
  • HBGF-8,
  • HBBM,
  • HB-GAM,
  • heparin-binding neurite outgrowth-promoting factor 1,

View in BioMuta


Pleiotrophin, or PTN, is a secreted growth factor found in osteoblasts and brain tissue. PTN induces neurite outgrowth and is mitogenic for fibroblasts, epithelial, and endothelial cells. It binds anaplastic lymphoma kinase (ALK) which induces MAPK pathway activation, an important step in the anti-apoptotic signaling of PTN and regulation of cell proliferation.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


Pleiotrophin has been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker. Pleiotrophin was also observed up-regulated in lung cancer in this study. Others studies have suggested that pleiotrophin may be an early indicator of lung cancer and might be of use in monitoring the efficacy of therapy.

Performance Comment

PTN, also known as pleiotrophin, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.